Drug Profile


Alternative Names: Immune therapeutic vaccine-1; Inactivated pepsin fraction HIV vaccine; IPF-ITV Phases; IPF-ITV-1; Irreversible pepsin fraction HIV vaccine; ITV-1

Latest Information Update: 28 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source
  • Developer Immunotech Laboratories
  • Class AIDS vaccines; Antivirals; Peptide vaccines
  • Mechanism of Action HIV envelope protein gp120 inhibitors; HIV envelope protein gp41 inhibitors; HIV fusion inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections
  • Phase II Hepatitis C

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for clinical-Phase-Unknown development in HIV-infections in South Africa (Parenteral, Suspension)
  • 22 Jun 2017 Immunotech Laboratories anticipates to complete the validation documentation and registration process for the manufacture of ITV 1 and submit an application to the Bulgarian Drug Administration by the end of September 2017
  • 14 Jun 2017 Phase-III clinical trials in HIV infections in Bulgaria prior to June 2017 (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top